FDG-PET in the clinical management of Hodgkin lymphoma

Critical Reviews in Oncology/Hematology

Volumn 52, Issue 1, 2004, Pages 19-32

  Hutchings, Martin ^a   Eigtved, Annika I ^a   Specht, Lena ^b  

^a PET and Cyclotron Unit   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

18F; Fluorodeoxyglucose; Hodgkin; Lymphoma; Positron emission tomography

Indexed keywords

2 FLUORO 2 DEOXY DEXTRO GLUCOSE F 18; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MEDICAL ASSESSMENT; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; TREATMENT PLANNING;

DRUG MONITORING; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT;

EID: 4444246555     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.05.007     Document Type: Review

References (100)

1. Swerdlow A.J. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 30(Suppl. 1):2003;S3-S12
2. Kogel K.E., Sweetenham J.W. Current therapies in Hodgkin's disease. Eur J Nucl Med Mol Imaging. 30(Suppl. 1):2003;S19-S27
3. Lund M.B., Kongerud J., Nome O., et al. Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol. 6:1995;495-501
4. Hancock S.L., Hoppe R.T. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol. 6:1996;225-242
5. Henry-Amar M., Somers R. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. Semin Oncol. 17:1990;758-768
6. Hoppe R.T. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 8(Suppl. 1):1997;115-118
7. Specht L., Gray R.G., Clarke M.J., Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol. 16:1998;830-843
8. Kotzerke J., Guhlmann A., Moog F., Frickhofen N., Reske S.N. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med. 26:1999;31-38
9. Mijnhout G.S., Hooft L., van Tulder M.W., et al. How to perform a comprehensive search for FDG-PET literature. Eur J Nucl Med. 27:2000;91-97
10. Mijnhout G.S., Hoekstra O.S., van Tulder M.W., Teule G.J., Deville W.L. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 91:2001;1530-1542
11. Bastiaannet E., Groen H., Jager P.L., et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 30:2004;83-101
12. Irwig L., Tosteson A.N., Gatsonis C., et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 120:1994;667-676
13. Deeks J.J. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 323:2001;157-162
14. Warburg O. Über den Stoffwechsel der Tumoren: arbeiten aus dem Kaiser Wilhelm-Institut für Biologie, Berlin-Dahlem. Berlin: Springer; 1926.
15. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 28:1987;288-292
16. Leskinen-Kallio S., Ruotsalainen U., Nagren K., Teras M., Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med. 32:1991;1211-1218
17. Okada J., Yoshikawa K., Imazeki K., et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med. 32:1991;686-691
18. Okada J., Yoshikawa K., Itami M., et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 33:1992;325-329
19. Lapela M., Leskinen S., Minn H.R., et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 86:1995;3522-3527
20. Rodriguez M., Rehn S., Ahlstrom H., Sundstrom C., Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med. 36:1995;1790-1796
21. Newman J.S., Francis I.R., Kaminski M.S., Wahl R.L. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology. 190:1994;111-116
22. Specht L. Prognostic factors in Hodgkin's disease. Semin Radiat Oncol. 6:1996;146-161
23. Munker R., Stengel A., Stabler A., Hiller E., Brehm G. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases. Cancer. 76:1995;1460-1466
24. Front D., Israel O. Present state and future role of gallium-67 scintigraphy in lymphoma. J Nucl Med. 37:1996;530-532
25. Kostakoglu L., Leonard J.P., Kuji I., et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 94:2002;879-888
26. Wirth A., Seymour J.F., Hicks R.J., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 112:2002;262-268
27. Moog F., Bangerter M., Diederichs C.G., et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 203:1997;795-800
28. Moog F., Bangerter M., Diederichs C.G., et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 206:1998;475-481
29. Stumpe K.D., Urbinelli M., Steinert H.C., et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 25:1998;721-728
30. Hoh C.K., Glaspy J., Rosen P., et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 38:1997;343-348
31. Jerusalem G., Warland V., Najjar F., et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun. 20:1999;13-20
32. Shah N., Hoskin P., McMillan A., et al. The impact of FDG positron emission tomography imaging on the management of lymphomas. Brit J Radiol. 73:2000;482-487
33. Buchmann I., Reinhardt M., Elsner K., et al. 2-(Fluorine-18)fluoro-2- deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 91:2001;889-899
34. Bangerter M., Moog F., Buchmann I., et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol. 9:1998;1117-1122
35. Wiedmann E., Baican B., Hertel A., et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma. 34:1999;545-551
36. Partridge S., Timothy A., O'Doherty M.J., et al. 2-Fluorine-18-fluoro-2- deoxy-D-glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol. 11:2000;1273-1279
37. Hueltenschmidt B., Sautter-Bihl M.L., Lang O., et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 91:2001;302-310
38. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica. 86:2001;266-273
39. Weihrauch M.R., Re D., Bischoff S., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol. 81:2002;20-25
40. Menzel C., Dobert N., Mitrou P., et al. Positron emission tomography for the staging of Hodgkin's lymphoma - increasing the body of evidence in favor of the method. Acta Oncol. 41:2002;430-436
41. Cohade C., Wahl R.L. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography - clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med. 33:2003;228-237
42. Rankin S.C. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging. 30(Suppl. 1):2003;S56-S64
43. Gupta RK, Gospodarowicz MK, Lister TA. Clinical evaluation and staging of Hodgkin's disease. In: Mauch P, Armitage JO, Diehl V, Hoppe R, Weiss LM, editors. Hodgkin's disease. Philadelphia: Lippincott Williams and Wilkins; 1999, p. 223-240.
44. Front D., Bar-Shalom R., Mor M., et al. Hodgkin disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Radiology. 210:1999;487-491
45. Castellino RA, Podoloff DA. Diagnostic radiology and nuclear medicine imaging. In: Mauch P, Armitage JO, Diehl V, Hoppe R, Weiss LM, editors. Hodgkin's disease. Philadelphia: Lippincott Williams and Wilkins; 1999, p. 241-262.
46. Djulbegovic B., Hendler F.J., Hamm J., Hadley T., Woodcock T.M. Residual mediastinal mass after treatment of Hodgkin's disease: a decision analysis. Med Hypotheses. 38:1992;166-175
47. Glenn L.D., Kumar P.P. The residual mediastinal mass following radiation therapy for Hodgkin's disease. Am J Clin Oncol. 14:1991;16-24
48. Lister T.A., Crowther D., Sutcliffe S.B., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 7:1989;1630-1636
49. Canellos G.P. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 6:1988;931-933
50. Carde P., Koscielny S., Franklin J., et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol. 13(Suppl. 1):2002;86-91
51. Salloum E., Brandt D.S., Caride V.J., et al. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. J Clin Oncol. 15:1997;518-527
52. Hagemeister F.B., Purugganan R., Podoloff D.A., et al. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol. 5(Suppl. 2):1994;59-63
53. Belhocine T., Steinmetz N., Hustinx R., et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 8:2002;2766-2774
54. Hoekstra O.S., Ossenkoppele G.J., Golding R., et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18- fluorodeoxyglucose scintigraphy. J Nucl Med. 34:1993;1706-1710
55. Hoekstra O.S., van Lingen A., Ossenkoppele G.J., Golding R., Teule G.J. Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography. Eur J Nucl Med. 20:1993;1214-1217
56. Romer W., Hanauske A.R., Ziegler S., et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 91:1998;4464-4471
57. Spaepen K., Stroobants S., Dupont P., et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 13:2002;1356-1363
58. The International non-Hodgkin's Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329:987-94.
59. Jerusalem G., Beguin Y., Fassotte M.F., et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 85:2000;613-618
60. Kostakoglu L., Coleman M., Leonard J.P., et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 43:2002;1018-1027
61. Spaepen K., Stroobants S., Dupont P., et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 30:2003;682-688
62. Lowe V.J., Wiseman G.A. Assessment of lymphoma therapy using (18)F-FDG PET. J Nucl Med. 43:2002;1028-1030
63. Segall G.M. FDG PET imaging in patients with lymphoma: a clinical perspective. J Nucl Med. 42:2001;609-610
64. Front D., Ben Haim S., Israel O., et al. Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology. 182:1992;359-363
65. Wylie B.R., Southee A.E., Joshua D.E., et al. Gallium scanning in the management of mediastinal Hodgkin's disease. Eur J Haematol. 42:1989;344-347
66. Bangerter M., Kotzerke J., Griesshammer M., et al. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 38:1999;799-804
67. Cremerius U., Fabry U., Neuerburg J., et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 19:1998;1055-1063
68. Cremerius U., Fabry U., Kroll U., et al. Clinical value of FDG PET for therapy monitoring of malignant lymphoma - results of a retrospective study in 72 patients. Nuklearmedizin. 38:1999;24-30
69. de Wit M., Bumann D., Beyer W., et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 8(Suppl. 1):1997;57-60
70. de Wit M., Bohuslavizki K.H., Buchert R., et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol. 12:2001;29-37
71. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 94:1999;429-433
72. Maisey N.R., Hill M.E., Webb A., et al. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer. 36:2000;200-206
73. Mikhaeel N.G., Timothy A.R., Hain S.F., O'Doherty M.J. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 11(Suppl. 1):2000;147-150
74. Naumann R., Vaic A., Beuthien-Baumann B., et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Brit J Haematol. 115:2001;793-800
75. Spaepen K., Stroobants S., Dupont P., et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Brit J Haematol. 115:2001;272-278
76. Weihrauch M.R., Re D., Scheidhauer K., et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 98:2001;2930-2934
77. Zinzani P.L., Magagnoli M., Chierichetti F., et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 10:1999;1181-1184
78. Zinzani P.L., Chierichetti F., Zompatori M., et al. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma. 43:2002;1239-1243
79. Guay C., Lepine M., Verreault J., Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med. 44:2003;1225-1231
80. Lavely W.C., Delbeke D., Greer J.P., et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys. 57:2003;307-315
81. Dittmann H., Sokler M., Kollmannsberger C., et al. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep. 8:2001;1393-1399
82. Lang O., Bihl H., Hultenschmidt B., Sautter-Bihl M.L. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther Onkol. 177:2001;138-144
83. Spaepen K., Stroobants S., Verhoef G., Mortelmans L. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging. 30(Suppl. 1):2003;S97-105
84. Foss A.A., Andersen A., Nome O., et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol. 13:2002;1786-1791
85. Hoskin P. The price of anticancer intervention. Secondary malignancies after radiotherapy. Lancet Oncol. 3:2002;577-578
86. Loeffler M., Brosteanu O., Hasenclever D., et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. 16:1998;818-829
87. Kiffer J.D., Berlangieri S.U., Scott A.M., et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 19:1998;167-177
88. Ciernik I.F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 57:2003;853-863
89. Nestle U., Hellwig D., Schmidt S., et al. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer. Mol Imaging Biol. 4:2002;257-263
90. Aleman B.M., Raemaekers J.M., Tirelli U., et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 348:2003;2396-2406
91. Canellos GP, Horwich A. Management of recurrent Hodgkin's disease. In: Mauch P, Armitage JO, Diehl V, Hoppe R, Weiss LM, editors. Hodgkin's disease. Philadelphia: Lippincott Williams and Wilkins; 1999, p. 507-519.
92. Jerusalem G., Beguin Y., Fassotte M.F., et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol. 14:2003;123-130
93. Torrey M.J., Poen J.C., Hoppe R.T. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol. 15:1997;1123-1130
94. Valk P.E. Randomized controlled trials are not appropriate for imaging technology evaluation. J Nucl Med. 41:2000;1125-1126
95. Nettelbladt O.S., Sundin A.E., Valind S.O., et al. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med. 39:1998;640-647
96. Nuutinen J., Leskinen S., Lindholm P., et al. Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. Eur J Nucl Med. 25:1998;729-735
97. Rau F.C., Weber W.A., Wester H.J., et al. O-(2-[(18)F]Fluoroethyl)-L- tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging. 29:2002;1039-1046
98. Buchmann I., Vogg A.T., Glatting G., et al. [18F]5-Fluoro-2-deoxyuridine- PET for imaging of malignant tumors and for measuring tissue proliferation. Cancer Biother Radiopharm. 18:2003;327-337
99. Wagner M., Seitz U., Buck A., et al. 3′-[18F]Fluoro-3′- deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 63:2003;2681-2687
100. Mikhaeel N.G., Timothy A.R., O'Doherty M.J., Hain S., Maisey M.N. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT. Leuk Lymphoma. 39:2000;543-553